Daito Pharmaceutical Co.,Ltd. (TYO:4577)

Market Cap	33.17B +6.3%
Revenue (ttm)	50.77B +3.9%
Net Income	2.96B +36.1%
EPS	99.47 +40.2%
Shares Out	27.60M
PE Ratio	12.08
Forward PE	13.33
Dividend	40.00 (3.33%)
Ex-Dividend Date	May 28, 2026

Volume	56,600
Open	1,195.00
Previous Close	1,197.00
Day's Range	1,195.00 - 1,217.00
52-Week Range	970.00 - 1,521.00
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 10, 2026

About Daito Pharmaceutical

Daito Pharmaceutical Co.,Ltd. engages in the manufacture and sale of pharmaceutical products in Japan and internationally. It offers active pharmaceutical ingredients for generic drugs; develops and manufactures generic and over-the-counter drugs; and contract manufacturing services for ethical drugs. The company is also involved in the wholesale of pharmaceutical and veterinary medicine. It exports its products to the United States, as well as European and Asian countries. The company was formerly known as Daito Corporation and changed its nam...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1942
• Employees: 1,073
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4577

Financial Performance

In fiscal year 2025, Daito Pharmaceutical's revenue was 50.64 billion, an increase of 7.99% compared to the previous year's 46.90 billion. Earnings were 1.91 billion, a decrease of -42.09%.